文献速递胃肠动力与功能性疾病

薄荷油治疗肠易激综合征:随机安慰剂对照试验

Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究为6周随机双盲安慰剂对照试验,纳入符合罗马IV标准且IBS-SSS≥175的肠易激综合征患者,按1:2随机接受肠溶薄荷油180mg每日三次或安慰剂。主要终点为IBS-SSS评分从基线至6周的平均变化,结果显示两组均有显著改善,但组间差异无统计学意义(P=0.97)。

要点

  • 薄荷油与安慰剂均使IBS-SSS评分显著改善,但组间差异无统计学意义。
  • 薄荷油组IBS-SSS平均改善90.8(SD=75.3),安慰剂组100.3(SD=99.6)。
  • 效应量小(d=-0.11),次要终点及敏感性分析均无显著组间差异。

核心结论

  • 薄荷油与安慰剂均对IBS症状产生有临床意义的改善,但两组间无显著差异。

研究设计与样本

  • 美国单中心6周随机双盲安慰剂对照试验,纳入符合罗马IV标准且IBS-SSS≥175的IBS患者,按1:2随机接受肠溶薄荷油180mg每日三次或安慰剂。

主要发现

  • 改良意向性分析显示,薄荷油组IBS-SSS平均改善90.8(SD=75.3),安慰剂组100.3(SD=99.6)。
  • 组间差异无统计学意义(P=0.97),效应量小(d=-0.11)。
  • 次要终点两组均有显著改善,但组间均无统计学显著差异。
  • 采用多重插补的敏感性分析结果相似,所有结局指标均无显著组间差异。

临床怎么用

  • 薄荷油对IBS的疗效与安慰剂无显著差异,临床决策需结合患者个体情况并告知证据局限性。

局限性

  • 单中心研究,样本量可能有限,需进一步大型严谨试验验证薄荷油在IBS治疗中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Peppermint oil is often used to treat irritable bowel syndrome (IBS); however, the overall quality of previous studies is low, and findings have been heterogeneous. This study aimed to compare the effects of peppermint oil vs placebo in relieving IBS symptoms. METHODS: In a 6-week, randomized, double-blind, placebo-controlled trial at a single academic center in the United States, individuals diagnosed with IBS (Rome IV criteria), with moderate to severe symptoms based on the IBS Severity Scoring System (IBS-SSS score ≥175), were randomized to enteric-coated peppermint oil 180 mg 3 times daily vs placebo in a 1:2 ratio. The primary outcome was mean change in IBS-SSS scores from baseline to 6-week endpoint. RESULTS: A modified intent-to-treat analysis revealed that there were substantial mean improvements from baseline to 6-week endpoint in the main outcome measure (IBS-SSS) for both peppermint oil (90.8, SD = 75.3) and placebo (100.3, SD = 99.6). Although the peppermint oil group reported numerically lower improvement than the placebo group, the effect size was small (d = -0.11), and the difference between the groups was not statistically significant (P = 0.97). Similarly, both groups reported substantial improvements on the secondary endpoints; but again, there were no statistically significant differences between the groups on any of the secondary measures. Sensitivity analyses using multiple imputation to replace missing data produced similar results and revealed no significant differences between peppermint oil and placebo on any outcome measure. DISCUSSION: Peppermint oil and placebo both showed clinically meaningful improvement in IBS symptoms. However, there were no significant differences between the groups. Further large, rigorous trials are needed to evaluate the role of peppermint oil for the treatment of IBS.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Nee J, Ballou S, Kelley JM, et al. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial. Am J Gastroenterol. 2021. PMID: 34319275. doi:10.14309/ajg.0000000000001395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。